Torrent Pharmaceuticals Launches Semaglutide Formulations in India
Filing Summary
Torrent Pharmaceuticals Ltd has introduced oral and injectable formulations of Semaglutide in India under the brands Sembolic and Semalix. This launch marks the company’s entry into the GLP-1 therapy segment, targeting metabolic disorders such as type-2 diabetes and obesity. The injectable formulation is priced at Rs. 3,999 per month. Torrent Pharma is the first Indian company to offer generic oral Semaglutide. The company, with annual revenues exceeding Rs 11,500 crores, focuses on chronic and sub-chronic therapies and operates in over 50 countries.
Torrent Pharmaceuticals Ltd announced the launch of its Semaglutide brands, Sembolic and Semalix, in India on March 21, 2026. The company has introduced both oral and injectable formulations, expanding its presence in the treatment of metabolic disorders, specifically type-2 diabetes and obesity. The injectable formulation is available at a starting price of Rs. 3,999 per month.
The launch positions Torrent Pharma as the first company in India to offer a generic oral version of Semaglutide. This development is part of the company’s strategy to enter the GLP-1 therapy segment, which is used for managing type-2 diabetes and obesity. GLP-1 receptor agonists enhance insulin secretion, reduce glucagon levels, and help regulate appetite, contributing to decreased haemoglobin A1c (HbA1c) levels, weight loss, and reduced cardiovascular risks.
Torrent Pharmaceuticals, with annual revenues exceeding Rs 11,500 crores, is a leading entity within the Torrent Group, which has group revenues of approximately Rs 45,000 crores. Following its acquisition of JB Pharma, Torrent is ranked fifth in the Indian Pharmaceuticals Market. The company is also among the top five in therapeutic segments including Cardiovascular, Gastro Intestinal, Central Nervous System, Pain Management, and Cosmo-Dermatology.
Approximately 76% of Torrent’s revenues in India are derived from chronic and sub-chronic therapies. The company operates in over 50 countries and holds the top position among Indian pharmaceutical companies in Brazil and Germany. Torrent Pharmaceuticals has eight manufacturing facilities, five of which are approved by the USFDA. The company has invested significantly in research and development, employing over 750 scientists to support its growth in domestic and international markets.